Tango Therapeutics, Inc. (TNGX) Total liabilities 2020–2025
Tango Therapeutics, Inc. (TNGX) total liabilities at each fiscal year-end, per SEC filings.
$52.5MFY2025 · since FY2020: $168.7M → $52.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $52.5M | -55.1% |
| FY2024 | $117.0M | -21.7% |
| FY2023 | $149.5M | -20.1% |
| FY2022 | $187.0M | +20.3% |
| FY2021 | $155.4M | -7.9% |
| FY2020 | $168.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More TNGX financial trends
TNGX RevenueTNGX Net incomeTNGX Net marginTNGX Gross profitTNGX Gross marginTNGX Operating incomeTNGX Operating marginTNGX Operating cash flowTNGX Free cash flowTNGX Capital expendituresTNGX Return on equityTNGX Stock buybacksTNGX Dividends paidTNGX Total assetsTNGX Shareholders’ equityTNGX overview →